NCT05061004ClinicalTrials.gov

Cephea Early Feasibility Study

En recrutementAccepte des participants actuellement, selon la fiche du registre.

Contacter cette étude

En bref

The objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) in…

Interventionnelle90 participants recherchés22 sites2 pays

Catégories

Cardiovasculaire100%

Enregistré dans 1 registre

ClinicalTrials.govNCT05061004Ouvrir cette fiche sur ClinicalTrials.govSynchronisé la semaine dernière

Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.

Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.

Cette étude vous intéresse ?

Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

Present: Registered before enrolment beganFirst posted 2021-09-29; recorded start 2022-04-28
Present: Has a defined primary outcomeA primary outcome measure is listed in the record
Present: The primary outcome states a time frameThe primary outcome measure records a time frame
Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
Not stated: A comparison group is not stated in the registry recordThe record describes a single study arm
Not stated: Open label (no blinding)Masking is recorded as none (open label)
Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
Present: Sponsor has 82 other studies in this databaseCounted from the lead sponsor named in the record (Abbott Medical Devices)
Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database

The record lists 1 condition.
Lead sponsor type recorded as: industry.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built

Randomised allocation0/20
Allocation not stated in the record
Blinding0/20
Open-label
Control arm0/15
No comparator arm stated in the record
Primary-outcome specificity10/10
Named primary outcome with a defined time frame
Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
Multi-centre8/8
Multi-centre: 22 sites
Data monitoring committee0/7
Data monitoring committee not stated in the record
Prospective registration5/5
Registered before the study start date
Protocol / SAP posted0/5
No protocol or SAP posted to the registry

ScaleSMALL

A small study, international in scope: 90 participants (target), run at 22 sites, across 2 countries.

How this score is built

Enrolment15/40
50 participants (target)
Site count16/25
22 sites
Country count7/15
2 countries
Planned duration10/10
Planned over about 108 months
Sponsor scale7/10
Abbott Medical Devices has led 83 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built

Investigator standing0/100
No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Résumé

Affections

Mitral Regurgitation

Éligibilité

Éligibilité
Sexe	Tous
Âges	18 Years – Aucun maximum
Volontaires sains	Non

Éligibilité telle qu'elle figure dans le registre

Key Inclusion Criteria: * Mitral valve disease resulting in mitral regurgitation (MR ≥ Grade III) and/or severe mitral valve stenosis (mitral valve area ≤ 1.5cm² and/or mean transmitral gradient ≥10 mmHg at normal heart rate) per American Society of Echocardiography criteria. * LVEF ≥ 30% * In the judgement of the Site Heart Team, transcatheter therapy is deemed more appropriate than open heart surgery. Key Exclusion Criteria: * Prior surgical or interventional treatment that interferes with the Cephea valve delivery or function. * Need for emergent or urgent surgery.

Éligibilité en énoncés simples

Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.

Conception de l'étude

Conception de l'étude
Type d'étude	Interventionnelle
Phase	Sans objet
Répartition	Sans objet
Modèle d'intervention	SINGLE_GROUP
Objectif principal	TREATMENT
Insu	NONE (0)
Recrutement	90 participants recherchés

Promoteur et collaborateurs

Abbott Medical Devices Promoteur

Groupes et interventions

TreatmentEXPERIMENTAL
Treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) with the Cephea Mitral Valve System

Interventions

Dispositif Cephea Mitral Valve System
Transcatheter mitral valve replacement

Critères de jugement

Critère de jugement principal
Primary Safety Endpoint
Freedom from all-cause mortality, which will be assessed at 30 days post implant.
Délai 30 days post implant
Critère de jugement principal
Primary Effectiveness Endpoint
Proportion of subjects with reduction of MR to ≤ Grade I, will be assessed at 30 days post implant.
Délai 30 days post implant

Dates

Dates
Date de début	28 avril 2022 (réelle)
Achèvement principal	31 décembre 2026 (estimée)
Achèvement	1 mars 2031 (estimée)
Première publication	29 septembre 2021 (réelle)
Dernière mise à jour	11 septembre 2026
Résultats publiés	Non précisé dans la fiche du registre
Statut vérifié pour la dernière fois	décembre 2025

Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.

Lieux

20 sites sont en recrutement

Canada

Canada
Établissement	Ville	État ou région	Statut
Institut de Cardiologie de Montreal	Montreal	Quebec	Terminé
IUCPQ-ULaval	Québec	Quebec	Retiré

United States

United States
Établissement	Ville	État ou région	Statut
University of Michigan - Davis Medical Center	Ann Arbor	Michigan	En recrutement
Piedmont Heart Institute	Atlanta	Georgia	En recrutement
Emory University Hospital	Atlanta	Georgia	En recrutement
Atrium Health - Carolinas Medical Center	Charlotte	North Carolina	En recrutement
Northwestern Memorial Hospital	Chicago	Illinois	En recrutement
The Cleveland Clinic Foundation	Cleveland	Ohio	En recrutement
Houston Methodist	Houston	Texas	En recrutement
Cedars-Sinai Medical Center	Los Angeles	California	En recrutement
Minneapolis Heart Institute	Minneapolis	Minnesota	En recrutement
Ascension Saint Thomas	Nashville	Tennessee	En recrutement
Vanderbilt Heart & Vascular Institute	Nashville	Tennessee	En recrutement
New York-Presbyterian/Columbia University Medical Center	New York	New York	En recrutement
Sentara Norfolk General Hospital	Norfolk	Virginia	En recrutement
Banner-University Medical Center Phoenix	Phoenix	Arizona	En recrutement
Allegheny General Hospital - ASRI	Pittsburgh	Pennsylvania	En recrutement
University of California - Davis Medical Center	Sacramento	California	En recrutement
Swedish Medical Center	Seattle	Washington	En recrutement
Montefiore Medical Center - Moses Campus	The Bronx	New York	En recrutement
Los Robles Regional Medical Center	Thousand Oaks	California	En recrutement
Ascension Via Christi Hospitals Wichita	Wichita	Kansas	En recrutement

Documents de l'étude

Aucun document n'est lié dans cette fiche du registre.

Évolution au fil du temps

11 septembre 2026
Objectif de recrutement modifié
Enrollment target revised up from 50 to 90
5090

Registre: ClinicalTrials.gov · NCT########

https://xmedica.io/trials/ctgov/NCT05061004